↓ Skip to main content

Therapeutic Proteins

Overview of attention for book
Cover of 'Therapeutic Proteins'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Therapeutic proteins.
  3. Altmetric Badge
    Chapter 2 Synthetic antibody libraries.
  4. Altmetric Badge
    Chapter 3 The Construction of “Phylomer” Peptide Libraries as a Rich Source of Potent Inhibitors of Protein/Protein Interactions
  5. Altmetric Badge
    Chapter 4 Ribosome Display and Screening for Protein Therapeutics
  6. Altmetric Badge
    Chapter 5 Yeast display of engineered antibody domains.
  7. Altmetric Badge
    Chapter 6 Expression, Purification, and Characterization of Engineered Antibody CH2 and VH Domains.
  8. Altmetric Badge
    Chapter 7 Engineering of Affibody Molecules for Therapy and Diagnostics
  9. Altmetric Badge
    Chapter 8 Protein Design for Diversity of Sequences and Conformations Using Dead-End Elimination
  10. Altmetric Badge
    Chapter 9 Design and Generation of DVD-Ig™ Molecules for Dual-Specific Targeting
  11. Altmetric Badge
    Chapter 10 Engineering and Expression of Bibody and Tribody Constructs in Mammalian Cells and in the Yeast Pichia pastoris
  12. Altmetric Badge
    Chapter 11 Use of E. coli for the Production of a Single Protein
  13. Altmetric Badge
    Chapter 12 Folding Engineering Strategies for Efficient Membrane Protein Production in E. coli
  14. Altmetric Badge
    Chapter 13 Transient Expression Technologies: Past, Present, and Future
  15. Altmetric Badge
    Chapter 14 Stable Transfection Pools for Large Quantity of Protein Production
  16. Altmetric Badge
    Chapter 15 Mammalian Stable Expression of Biotherapeutics
  17. Altmetric Badge
    Chapter 16 Transgenic Expression of Therapeutic Proteins in Arabidopsis thaliana Seed
  18. Altmetric Badge
    Chapter 17 Methods for Chromatographic Removal of Endotoxin
  19. Altmetric Badge
    Chapter 18 Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
  20. Altmetric Badge
    Chapter 19 High-Throughput Quantitative N-Glycan Analysis of Glycoproteins
  21. Altmetric Badge
    Chapter 20 High-Throughput Multimodal Strong Anion Exchange Purification and N-Glycan Characterization of Endogenous Glycoprotein Expressed in Glycoengineered Pichia pastoris
  22. Altmetric Badge
    Chapter 21 Databases and tools in glycobiology.
  23. Altmetric Badge
    Chapter 22 Characterization of PEGylated Biopharmaceutical Products by LC/MS and LC/MS/MS
  24. Altmetric Badge
    Chapter 23 Identification of Asp Isomerization in Proteins by 18 O Labeling and Tandem Mass Spectrometry
  25. Altmetric Badge
    Chapter 24 Monitoring of Subvisible Particles in Therapeutic Proteins
  26. Altmetric Badge
    Chapter 25 Size-Exclusion Chromatography with Multi-angle Light Scattering for Elucidating Protein Aggregation Mechanisms
  27. Altmetric Badge
    Chapter 26 Computational Methods to Predict Therapeutic Protein Aggregation
  28. Altmetric Badge
    Chapter 27 Coarse-Grained Simulations of Protein Aggregation
  29. Altmetric Badge
    Chapter 28 Chitosan-based nanoparticles as delivery systems of therapeutic proteins.
  30. Altmetric Badge
    Chapter 29 Challenges in the Development and Manufacturing of Antibody–Drug Conjugates
Attention for Chapter 1: Therapeutic proteins.
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#12 of 13,872)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
29 news outlets
blogs
1 blog
twitter
2 X users
patent
1 patent
facebook
1 Facebook page
wikipedia
7 Wikipedia pages

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
904 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Therapeutic proteins.
Chapter number 1
Book title
Therapeutic Proteins
Published in
Methods in molecular biology, June 2012
DOI 10.1007/978-1-61779-921-1_1
Pubmed ID
Book ISBNs
978-1-61779-920-4, 978-1-61779-921-1
Authors

Dimitrov DS, Dimiter S. Dimitrov, Dimitrov, Dimiter S.

Abstract

Protein-based therapeutics are highly successful in clinic and currently enjoy unprecedented recognition of their potential. More than 100 genuine and similar number of modified therapeutic proteins are approved for clinical use in the European Union and the USA with 2010 sales of US$108 bln; monoclonal antibodies (mAbs) accounted for almost half (48%) of the sales. Based on their pharmacological activity, they can be divided into five groups: (a) replacing a protein that is deficient or abnormal; (b) augmenting an existing pathway; (c) providing a novel function or activity; (d) interfering with a molecule or organism; and (e) delivering other compounds or proteins, such as a radionuclide, cytotoxic drug, or effector proteins. Therapeutic proteins can also be grouped based on their molecular types that include antibody-based drugs, Fc fusion proteins, anticoagulants, blood factors, bone morphogenetic proteins, engineered protein scaffolds, enzymes, growth factors, hormones, interferons, interleukins, and thrombolytics. They can also be classified based on their molecular mechanism of activity as (a) binding non-covalently to target, e.g., mAbs; (b) affecting covalent bonds, e.g., enzymes; and (c) exerting activity without specific interactions, e.g., serum albumin. Most protein therapeutics currently on the market are recombinant and hundreds of them are in clinical trials for therapy of cancers, immune disorders, infections, and other diseases. New engineered proteins, including bispecific mAbs and multispecific fusion proteins, mAbs conjugated with small molecule drugs, and proteins with optimized pharmacokinetics, are currently under development. However, in the last several decades, there are no conceptually new methodological developments comparable, e.g., to genetic engineering leading to the development of recombinant therapeutic proteins. It appears that a paradigm change in methodologies and understanding of mechanisms is needed to overcome major challenges, including resistance to therapy, access to targets, complexity of biological systems, and individual variations.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 904 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 <1%
France 2 <1%
Switzerland 2 <1%
Germany 1 <1%
Italy 1 <1%
India 1 <1%
United Kingdom 1 <1%
Canada 1 <1%
Austria 1 <1%
Other 4 <1%
Unknown 885 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 191 21%
Researcher 133 15%
Student > Master 129 14%
Student > Bachelor 105 12%
Student > Doctoral Student 39 4%
Other 111 12%
Unknown 196 22%
Readers by discipline Count As %
Agricultural and Biological Sciences 202 22%
Biochemistry, Genetics and Molecular Biology 173 19%
Chemistry 94 10%
Pharmacology, Toxicology and Pharmaceutical Science 53 6%
Engineering 45 5%
Other 126 14%
Unknown 211 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 243. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 January 2024.
All research outputs
#147,174
of 24,661,808 outputs
Outputs from Methods in molecular biology
#12
of 13,872 outputs
Outputs of similar age
#619
of 167,753 outputs
Outputs of similar age from Methods in molecular biology
#2
of 44 outputs
Altmetric has tracked 24,661,808 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,872 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 167,753 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 44 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.